Sleep apnea treatment has long puzzled cardiologists because clinical trials consistently failed to show heart benefits from CPAP therapy, despite strong biological rationale. This disconnect may finally have an explanation that transforms how we approach the 936 million adults worldwide living with obstructive sleep apnea. Machine learning analysis of 2,687 patients from the landmark SAVE cardiovascular trial reveals that CPAP therapy produces dramatically different outcomes depending on individual patient characteristics. Using causal survival forest algorithms, researchers identified distinct patient subgroups with opposing treatment responses. The most striking finding: patients predicted to benefit from CPAP showed 100-fold better cardiovascular event-free survival when treated, while those predicted to be harmed experienced over 100-fold worse outcomes with the same therapy. This represents one of the largest treatment effect variations documented in cardiovascular medicine. The analysis suggests that roughly one-third of non-sleepy sleep apnea patients derive substantial cardiovascular protection from CPAP, while another third may actually face increased risk. This finding reframes decades of inconclusive CPAP research as a precision medicine challenge rather than a therapeutic failure. The implications extend beyond sleep medicine into broader questions about population-level treatment approaches versus individualized care. However, the analysis relies on post-hoc modeling of existing trial data rather than prospective validation. Clinical implementation would require developing practical tools to identify which patients belong in each response category, likely involving combinations of genetic, metabolic, and physiological markers not yet standardized for routine use.